Promising combo for brain metastases in HER2+ breast cancer falls short
Disease control
Terminated
This phase II trial tested a combination of two drugs, ASLAN001 and capecitabine, in patients with HER2-positive breast cancer that had spread to the brain and continued to grow despite radiation. The study aimed to see if the treatment could shrink brain tumors. However, the tri…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 26, 2026 16:16 UTC